Cytokines and acute heart failure

In patients with chronic heart failure, ongoing myocardial injury partially results from activation of the inflammatory system, with production and release of proinflammatory cytokines, activation of the complement system, production of autoantibodies, overexpression of major histocompatibility complex molecules, and expression of adhesion molecules that may perpetuate the inflammatory state. Acute decompensated heart failure modifies the course of chronic heart failure and worsens outcomes via a combination of potential mechanisms, including neurohormonal activation, apoptosis, and the inflammatory cascade. Proinflammatory cytokines, including tumor necrosis factor-&agr; and interleukin-6, play a pathogenetic role in chronic heart failure, and anti-inflammatory immune therapy is currently under investigation. In acute decompensation of chronic heart failure, the change in the inflammatory cytokine activation cascade is less clear. Larger investigational studies are needed to assess the exact roles of circulating and intracardiac cytokines in this particular patient population.

[1]  G. Torre-Amione.  Immune activation in chronic heart failure. , 2005, The American journal of cardiology.

[2]  K. Kataoka,et al.  Serial circulating concentrations of c‐reactive protein, interleukin (il)‐4, and il‐6 in patients with acute left heart decompensation , 1999, Clinical cardiology.

[3]  P. Lasierra,et al.  Time-course of changes in levels of interleukin 6 in acutely decompensated heart failure. , 2006, International journal of cardiology.

[4]  A. Demetris,et al.  Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. , 1997, Circulation.

[5]  A. Ogata,et al.  Hypoxic stress induces cardiac myocyte-derived interleukin-6. , 1995, Circulation.

[6]  N. Rose,et al.  Mast Cells and Innate Cytokines are Associated with Susceptibility to Autoimmune Heart Disease Following Coxsackievirus B3 Infection , 2004, Autoimmunity.

[7]  J. Lommi,et al.  Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. , 1997, European heart journal.

[8]  M. Entman,et al.  Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. , 1999, Circulation.

[9]  S. Colan,et al.  Gamma-globulin treatment of acute myocarditis in the pediatric population. , 1994, Circulation.

[10]  S. Ogawa,et al.  Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure. , 2001, Japanese circulation journal.

[11]  Z. Vered,et al.  Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. , 2003, The American journal of cardiology.

[12]  J. H. Johnson,et al.  The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. , 1992, The Journal of clinical investigation.

[13]  I. Kallikazaros,et al.  The Ca2+‐sensitizer levosimendan improves oxidative damage, BNP and pro‐inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine , 2005, European journal of heart failure.

[14]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[15]  D. Mann,et al.  Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.

[16]  R. Peshock,et al.  Factor-Cardiac Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis , 1998 .

[17]  G. Noon,et al.  Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. , 1999, Circulation.

[18]  R. Peshock,et al.  Cardiac Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-α , 1998 .

[19]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[20]  M. Satoh,et al.  Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. , 1997, Journal of the American College of Cardiology.

[21]  A. Yao,et al.  Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. , 1994, Circulation research.

[22]  M. Levin,et al.  Characterization of a myocardial depressant factor in meningococcal septicemia* , 2002, Critical care medicine.

[23]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[24]  G. Lip,et al.  Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[25]  R. Peshock,et al.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.

[26]  M. Bristow,et al.  Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. , 1986, Circulation.

[27]  C. Lavie,et al.  The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. , 1996, Chest.

[28]  G. Schuler,et al.  Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure , 2003, European journal of heart failure.

[29]  R. Holubkov,et al.  Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  D. Hossfeld,et al.  TNF-induced cardiomyopathy , 1990, The Lancet.

[31]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[32]  F. Zannad,et al.  Clinical definition and epidemiology of advanced heart failure. , 1998, American heart journal.

[33]  J. Shelhamer,et al.  A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. , 1985, The Journal of clinical investigation.

[34]  W. Paulus,et al.  Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure. , 1998, European heart journal.

[35]  A. Timmis,et al.  Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. , 1993, BMJ.

[36]  H. Oral,et al.  Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. , 1997, Circulation research.

[37]  N. Rose,et al.  IL-12 Receptor β1 and Toll-Like Receptor 4 Increase IL-1β- and IL-18-Associated Myocarditis and Coxsackievirus Replication1 , 2003, The Journal of Immunology.

[38]  D. Mann,et al.  Expression and functional significance of tumor necrosis factor receptors in human myocardium. , 1995, Circulation.

[39]  F. Pagani,et al.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. , 1992, The Journal of clinical investigation.

[40]  H. Miller,et al.  Role of cytokines in heart failure. , 1998, American heart journal.

[41]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[42]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[43]  Anand Kumar,et al.  Myocardial dysfunction in the patient with sepsis , 2002, Current opinion in critical care.

[44]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[45]  Ziya Kaya,et al.  Complement Receptor 1 and 2 Deficiency Increases Coxsackievirus B3-Induced Myocarditis, Dilated Cardiomyopathy, and Heart Failure by Increasing Macrophages, IL-1β, and Immune Complex Deposition in the Heart1 , 2006, The Journal of Immunology.

[46]  M. Kinoshita,et al.  Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. , 2003, International journal of cardiology.

[47]  R. Holubkov,et al.  Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy , 2001, Circulation.

[48]  G. MacGowan,et al.  Circulating interleukin-6 in severe heart failure. , 1997, The American journal of cardiology.

[49]  K. Matsushima,et al.  Relationship between interleukin 1 (IL1), tumor necrosis factor (TNF) and a neutrophil attracting peptide (NAP-1) , 2005, Agents and Actions.

[50]  L. Vaca,et al.  Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. , 1993, The Journal of clinical investigation.

[51]  S. Anker,et al.  How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. , 2002, International journal of cardiology.

[52]  G. MacGowan,et al.  Intravenous immune globulin in the therapy of peripartum cardiomyopathy. , 1999, Journal of the American College of Cardiology.